SCHEMBL6490488

SCHEMBL6490488

Nc1ccc(CC(=O)Nc2ccccn2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.74
MEN1 O00255 2/20 0.74
SLC6A2 P23975 1/20 0.74
SLC6A3 Q01959 1/20 0.74
GAA P10253 2/20 0.63
SMN1; SMN2 Q16637 3/20 0.56
ESR1 P03372 1/20 0.56
POLB P06746 1/20 0.56
STAT3 P40763 1/20 0.56
ESR2 Q92731 1/20 0.56
RAB9A P51151 5/20 0.54
NPC1 O15118 3/20 0.54
ALDH1A1 P00352 2/20 0.54
PKM P14618 2/20 0.53
HDAC3 O15379 3/20 0.52
HDAC4 P56524 3/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC7 Q8WUI4 3/20 0.52
HDAC2 Q92769 3/20 0.52
HDAC10 Q969S8 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908980 0.87 KMT2A (0.82) KMT2AMEN1SLC6A2SLC6A3GAA
SCHEMBL29270879 0.85 KMT2A (1.00) KMT2AMEN1SLC6A2SLC6A3GAA
Difenpiramide SCHEMBL29238669 0.85 KMT2A (1.00) KMT2AMEN1SLC6A2SLC6A3GAA
Difenpiramide SCHEMBL23833 0.85 KMT2A (1.00) KMT2AMEN1SLC6A2SLC6A3GAA
SCHEMBL5182191 0.82 KMT2A (0.61) KMT2AMEN1SLC6A2SLC6A3GAA
SCHEMBL28194116 0.81 KMT2A (0.68) KMT2AMEN1SLC6A2SLC6A3GAA
SCHEMBL4575591 0.81 KMT2A (0.68) KMT2AMEN1SLC6A2SLC6A3GAA
SCHEMBL5161662 0.80 GAA (0.56) KMT2AMEN1SLC6A2SLC6A3GAA
SCHEMBL6492795 0.80 POLB (0.67) KMT2AMEN1SLC6A2SLC6A3GAA
SCHEMBL1674143 0.79 DEGS1 (0.71) KMT2AMEN1SLC6A2SLC6A3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR KMT2A 916/4885MEN1 3820/4885SLC6A2 1013/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 KMT2A 573/4885MEN1 1991/4885SLC6A2 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.